Author:
Rieckmann Peter,Ziemssen Tjalf,Penner Iris-Katarina,Raji Alaleh,Wagner Torsten,Richter Joachim,Zettl Uwe K.
Funder
Merck Serono GmbH, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Friedrich-Alexander-Universität Erlangen-Nürnberg
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference29 articles.
1. Sabaté E. Adherence to long-term therapies. Evidence for action. World Health Organization. 2003. http://apps.who.int/medicinedocs/pdf/s4883e/s4883e.pdf. Accessed 21 Mar 2022.
2. Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol. 2008;255(Suppl 6):87-92.eo.
3. Kern S, Reichmann H, Ziemssen T. Therapieadhärenz in der neurologischen Praxis [Treatment adherence in neurological practice]. Nervenarzt. 2008;79:877–90.
4. Evans C, Marrie RA, Zhu F, et al. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations: MS adherence and hospitalizations. Pharmacoepidemiol Drug Saf. 2017;26:702–11.
5. Burks J, Marshall TS, Ye X. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. Clinicoecon Outcomes Res. 2017;9:251–60.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献